Flash Finance

Novelix Pharmaceuticals Ltd536565Corporate

Healthcare Research, Analytics & Technology Latest results: Sep 2022 13 quarters of data
Consolidated Standalone
₹79.51
MCap ₹181 Cr
Novelix Pharmaceuticals Ltd — Stock analysis & AI research Novelix Pharmaceuticals Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1 Cr
Sales · Sep 2022
-49.6% YoY
₹-0 Cr
Operating Profit · Sep 2022
-226.7% YoY
-15.3%
OPM % · Sep 2022
-350.8% YoY
₹-0 Cr
Net Profit · Sep 2022
-142.9% YoY
₹-0.16
EPS · Sep 2022
-140.0% YoY

📝 Novelix Pharmaceuticals Ltd — results explained

Quarter ended September 2022 (Q2 FY23)

Novelix Pharmaceuticals Ltd reported revenue of ₹1 crore for the quarter ended September 2022 (Q2 FY23), down 49.6% from ₹2 crore in the same quarter last year, and down 8.8% sequentially over the June 2022 quarter.

The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.16.

Operating profit stood at ₹-0 crore — an operating margin (OPM) of -15.3%, compared with 6.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY22, Novelix Pharmaceuticals Ltd posted revenue of ₹9 crore, a decline of 6.7% over FY21, with a net loss of ₹2 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹4 crore with a net loss of ₹3 crore.

Valuation snapshot

At the current price of ₹79.51, 536565 has a market capitalisation of ₹181 crore.

Within the Healthcare Research, Analytics & Technology industry, it is the 7th-largest of the 10 companies we track by market value.

Shareholding pattern

As of Jul 2026, promoters held 54.29%, public shareholders 45.69% of Novelix Pharmaceuticals Ltd.

Promoter holding rose from 50.57% to 54.29% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹181 Cr
Current Price ?
₹79.5
P/E ?
N/A
Industry P/E ?
35.60
P/B ?
3.92
P/S ?
41.03
P/FCF ?
-6.94
Enterprise Value ?
₹185 Cr
EV/EBITDA ?
-62.77
PEG ?
N/A
Earnings Yield ?
-1.6%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹4 Cr
OPM ?
-66.8%
Profit after tax (TTM) ?
₹-3 Cr
EPS (TTM) ?
₹-1.12
ROCE ?
10.0%
ROE ?
-5.5%
ROA ?
-2.8%
Growth
Sales — latest qtr ?
₹1 Cr
PAT — latest qtr ?
₹-0 Cr
YoY qtr sales growth ?
-49.6%
YoY qtr profit growth ?
-142.9%
Sales growth (3y) ?
-6%
Sales growth (5y) ?
-1%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹4 Cr
Debt to Equity ?
0.09
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
54.29%
Change in promoter holding ?
2.32%
Pledged percentage ?
N/A
Market
Return 3 months ?
-0.4%
Return 6 months ?
48.1%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022 YoY % QoQ %
Sales 3332223421111 -49.6% -8.8%
Operating Profit -0-0-0-0-0-0-3-00-1-2-0-0 -226.7% -35.7%
Other Income 0000000000000 -81.2% -14.3%
Interest 0000000000000 — —
Depreciation 0000000000-000 -50.0% +0.0%
Profit Before Tax -0-00-0-0-0-3-00-1-1-0-0 -134.9% -66.7%
Net Profit -0-00-0-0-0-3-00-1-2-0-0 -142.9% -66.7%
EPS -0.21-0.150.04-0.11-0.21-0.26-4.05-0.190.40-0.77-1.67-0.09-0.16 -140.0% -77.8%
OPM % -11.5% -6.3% -3.8% -7.3% -6.0% -11.4% -130.7% -3.9% 6.1% -87.4% -237.7% -10.3% -15.3% -350.8% -48.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY21 FY22 TTM YoY %
Sales ₹9 Cr ₹9 Cr ₹4 Cr -6.7%
Operating Profit ₹-4 Cr ₹-3 Cr ₹-3 Cr +31.3%
OPM % -41.50% -30.55% -66.82% +26.4%
NPM % -40.74% -23.58% -57.73% +42.1%
Other Income ₹0 Cr ₹1 Cr ₹0 Cr +97.1%
Depreciation ₹0 Cr ₹0 Cr ₹0 Cr -54.5%
Interest ₹0 Cr ₹0 Cr ₹0 Cr -100.0%
EBIT ₹-4 Cr ₹-3 Cr ₹-3 Cr +32.6%
PBT ₹-4 Cr ₹-2 Cr ₹-3 Cr +45.7%
Tax — — — —
Net Profit ₹-4 Cr ₹-2 Cr ₹-3 Cr +46.0%
EPS ₹-4.63 ₹-2.23 ₹-2.69 +51.8%
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 881021 +110.0%
Reserves -1-1825 +212.5%
Borrowings 0004 —
Other Liabilities 001042 +320.0%
Total Liabilities 772792 +240.7%
Fixed Assets 0003 —
CWIP 0000 —
Investments 3300 —
Other Assets 442789 +229.6%
Total Assets 772792 +240.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -2-0-14-22 -57.1%
Cash from Investing Activity 003-2 -166.7%
Cash from Financing Activity 001126 +136.4%
Net Cash Flow -2-012 +100.0%
Free Cash Flow -2-0-14-26 -85.7%
CFO/OP —136%-9,771%-643% +93.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 361216163 -24.5%
Inventory Days 2221131042 +320.0%
Days Payable 140115116 +0.9%
Cash Conversion Cycle 24411411188 -20.7%
Working Capital Days 743346197122 -38.1%
ROCE % -1%0%1%10% +900.0%

👥 Shareholding (latest 4 periods)

Metric Dec 2025Mar 2026Jun 2026Jul 2026 % Chg
Promoters 51.97%49.43%50.57%54.29% +7.4%
Public 48.01%50.57%49.43%45.69% -7.6%
No. of Shareholders 2,9942,9753,1183,127 +0.3%

⚖️ Peer comparison

Industry: Healthcare Research, Analytics & Technology · 10 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 INDGN Indegene ₹597.05 14,377 35.8 3,812 401 16.7% 10.5% 23.6% -1.5% 39.7% -0.2%
2 SUVEN Suven Life ₹286.25 8,088 — 9 -353 -3955.0% -3815.2% 6.9% -71.9% 114.3% -148.5%
3 VIMTALABS Vimta Labs ₹637.20 2,847 35.7 419 80 34.4% 19.1% 18.0% 19.5% 11.3% 10.7%
4 FABTECH Fabtech Technologies ₹145.66 647 44.8 364 14 2.4% 4.0% — — 10.3% 168.7%
5 526853 Bilcare Ltd-$ ₹61.25 215 — 773 -6 9.1% -0.8% -6.9% 36.7% 21.2% 253.4%
6 TAKE Take Solutions ₹12.69 186 14.6 85 13 -2.0% 15.2% — -71.0% — 216.8%
7 536565 Novelix Pharmaceuticals ₹19.88 181 13.2 147 4 3.1% 2.5% 330.7% 2218.2% 65.2% 971.7%
8 538837 Jeevan Scientific ₹50.96 178 22.6 71 5 20.5% 7.2% 31.4% 1371.4% 107.7% 127.0%
9 543309 Adeshwar Meditex ₹27.50 24 31.2 56 1 4.9% 2.2% — — -30.4% -60.4%
10 540729 Vanta Bioscience ₹51.45 15 333.1 2 0 55.8% 6.1% — — 357.6% 240.9%
❓ Frequently asked questions
What was Novelix Pharmaceuticals Ltd's revenue in Q2 FY23?
Novelix Pharmaceuticals Ltd reported revenue of ₹1 crore for the quarter ended September 2022 (Q2 FY23), down 49.6% from ₹2 crore in the same quarter last year, and down 8.8% sequentially over the June 2022 quarter.
What was Novelix Pharmaceuticals Ltd's net profit in Q2 FY23?
The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.16.
What is 536565's market capitalisation and P/E ratio?
At the current price of ₹79.51, 536565 has a market capitalisation of ₹181 crore.
Who owns Novelix Pharmaceuticals Ltd? (shareholding pattern)
As of Jul 2026, promoters held 54.29%, public shareholders 45.69% of Novelix Pharmaceuticals Ltd.
TTM ends 2022-09-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI